Sign In
Buy BTAI
$1.26
-0.0400 (-3.08%)
At Close: Jun 23, 2026
NEW HAVEN, Conn., Feb. 04, 2021 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. ("BioXcel" or the "Company") (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence
Why BioXcel Therapeutics Stock Popped Today
04:54pm, Monday, 01'st Feb 2021
A Wall Street analyst has high hopes for the company.
4 of the Best Investments to Start 2021
11:24am, Wednesday, 13'th Jan 2021
High-growth names with positive catalysts that can outperform the markets make these some of the best investments to start 2021. The post 4 of the Best Investments to Start 2021 appeared first on Inve
BioXcel Therapeutics Has Compelling Upside Potential In Advance Of Multiple Data Readouts
01:48pm, Sunday, 27'th Dec 2020
BioXcel uses a proprietary AI program to screen for ways to repurpose old drugs and screen for useful biomarkers that can allow for faster, safer, and cheaper drug development. BioXcel's lead asset BX
The Story of 2020 … and Possibly 2021 … and What it Means for Your Investments
05:30pm, Saturday, 26'th Dec 2020
In the not-too-distant future, healthcare will look dramatically different from what we know today. From telemedicine to precision medicine to genetic therapy, the global healthcare industry is about
BioXcel Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference
07:00am, Thursday, 17'th Dec 2020
Company to present corporate update and plans for 2021
BioXcel Therapeutics Announces Grant by U.S. Department of Defense to Evaluate BXCL501 in Patients Suffering from PTSD
07:00am, Monday, 07'th Dec 2020
Grant will support clinical studies in patients with post-traumatic stress disorder related to alcohol and substance abuse Grant will support clinical studies in patients with post-traumatic stress di
BioXcel Therapeutics to Participate in the Jefferies Virtual London Healthcare Conference
07:00am, Friday, 13'th Nov 2020
NEW HAVEN, Conn., Nov. 13, 2020 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI” or the “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intellig
Initiated rolling submission of New Drug Application (“NDA”) with U.S. Food and Drug Administration (“FDA”)
Encouraging signals of activity in difficult-to-treat tumors observed in both ongoing trials with BXCL701 and pembrolizumab (KEYTRUDA®)
BioXcel Therapeutics to Host Third Quarter 2020 Operating and Financial Results Conference Call and Webcast
07:00am, Thursday, 05'th Nov 2020
NEW HAVEN, Conn., Nov. 05, 2020 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI” or “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence
Artificial Intelligence (AI) in Precision Medicine Market Growth, Share, Size, Trends, Top Companies and Forecast 2025
08:11pm, Wednesday, 07'th Oct 2020
Oct 07, 2020 (Market Insight Reports) --
Selbyville, Delaware Recently, Market Study Report, LLC, added a research on the ‘Artificial Intelligence (AI) in...
BioXcel Therapeutics: Big Upside Potential (NASDAQ:BTAI)
11:37am, Wednesday, 07'th Oct 2020
Today, we look at a promising CNS play called BioXcel Therapeutics. The shares have lost more than a third from their pre-secondary offering highs.
The
